Jazz Pharmaceuticals (JAZZ) Depreciation & Amortization (CF) (2016 - 2025)
Jazz Pharmaceuticals has reported Depreciation & Amortization (CF) over the past 16 years, most recently at $9.4 million for Q4 2025.
- Quarterly Depreciation & Amortization (CF) fell 0.91% to $9.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $41.6 million through Dec 2025, up 27.12% year-over-year, with the annual reading at $41.6 million for FY2025, 27.12% up from the prior year.
- Depreciation & Amortization (CF) was $9.4 million for Q4 2025 at Jazz Pharmaceuticals, down from $9.9 million in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $11.9 million in Q2 2025 and troughed at $4.8 million in Q1 2021.
- The 5-year median for Depreciation & Amortization (CF) is $7.7 million (2023), against an average of $8.1 million.
- Biggest five-year swings in Depreciation & Amortization (CF): skyrocketed 61.6% in 2021 and later fell 2.99% in 2023.
- Tracing JAZZ's Depreciation & Amortization (CF) over 5 years: stood at $7.3 million in 2021, then rose by 0.23% to $7.3 million in 2022, then increased by 4.14% to $7.6 million in 2023, then rose by 24.4% to $9.5 million in 2024, then fell by 0.91% to $9.4 million in 2025.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at $9.4 million, $9.9 million, and $11.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.